GO
Loading...

Enter multiple symbols separated by commas

Medicine

More

  • Zogenix says former obesity drug reduced seizures in study Wednesday, 27 May 2015 | 11:54 AM ET

    Zogenix said it plans to start late-stage testing of the drug in the second half of 2015, and it hopes to file for marketing approval in the U.S. and the European Union in late 2016.. Zogenix said research has long shown that it can reduce epileptic seizures, however. It is a component of Vivus Inc.' s anti-obesity drug Qsymia.

  • May 27- GlobeImmune Inc said its experimental hepatitis B drug did not meet the main goal of reducing infection in patients after 24 weeks, in a mid-stage trial. GlobeImmune is developing the drug, GS-4774, with Gilead Sciences Inc.. Companies developing hepatitis B drugs include Arrowhead Research Corp, Canada's Tekmira Pharmaceuticals Corp and Isis...

  • GlobeImmune, Gilead Hep B drug fails in mid-stage study Wednesday, 27 May 2015 | 6:50 AM ET

    May 27- GlobeImmune Inc said its experimental hepatitis B drug did not meet the main goal of reducing infection in patients after 24 weeks, in a mid-stage trial. However, the drug was found to reduce HBsAg, an antigen that indicates the strength of hepatitis B infection, after 48 weeks, the company said on Wednesday. GlobeImmune is developing the drug, GS-4774, with...

  • COPENHAGEN, May 26- Bavarian Nordic is hot property after striking two big vaccine deals but the small Danish company is not for sale, despite a wave of consolidation in the healthcare industry, its chief told Reuters. Boosting the immune system is now a top priority for cancer drug companies such as Bristol-Myers, Merck, Roche and AstraZeneca, fuelling renewed...

  • *OIE warns U.S. bird flu viruses could spread to Mexico. PARIS, May 26- An epidemic of bird flu that has devastated U.S. poultry flocks this year is likely to be under control within four months as the United States steps up measures to contain the virus, the head of the World Organisation for Animal Health said. However, there is a high risk that strains of the virus will...

  • WASHINGTON— Sticky plaque gets the most attention, but now healthy seniors at risk of Alzheimer's are letting scientists peek into their brains to see if another culprit is lurking. Reisa Sperling of Boston's Brigham and Women's Hospital and Harvard Medical School, who is leading the so-called A4 study. The A4 study— it stands for Anti-Amyloid Treatment in...

  • DES MOINES, Iowa— Egg prices reached record levels on Friday after a bird flu outbreak decimated the flock, leading to the death of more than 20 million egg-laying hens over the last month in the top producing state of Iowa. The virus spread appears to have slowed but not stopped. Carton egg prices reached a record Friday of $2.32 a dozen for Midwest large eggs, said...

  • May 21- Biotech firm Bluebird Bio Inc said its experimental gene therapy continued to exhibit a positive effect in an ongoing early-stage study of patients with rare types of blood disorders. The product, LentiGlobin, is being tested in patients with beta-thalassemia major and those with severe sickle cell disease, two hereditary conditions.

  • May 20- U.S. healthcare conglomerate Johnson& Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines. J&J said it would file for approval of daratumumab for the blood cancer multiple myeloma in the United...

  • NEW YORK, May 20- A U.S. group is trying to block patents in five countries for Gilead Sciences Inc's costly hepatitis C drug Sovaldi, in a bid to give almost 60 million afflicted people access to cheaper generic versions. In Argentina, Brazil, China, Russia and Ukraine, challenges have been filed against Gilead's patents or patent applications, the New York- based...

  • May 19- The U.S. Food and Drug Administration approved a longer-acting version of Johnson& Johnson's schizophrenia treatment, developed by the company's Janssen Pharmaceuticals unit. The FDA approved the drug, Invega Trinza, to be administered just four times a year, the longest dosing interval available for the treatment of the neurological disorder,...

  • INSIGHT-Is nicotine all bad? Tuesday, 19 May 2015 | 5:59 AM ET

    LONDON, May 19- Since he ditched Marlboro Lights five years ago, Daniel's fix is fruit-flavoured nicotine gum that comes in neat, pop-out strips. He gets through 12 to 15 pieces a day and says he has "packets of the stuff" stashed all over. Psychologists and tobacco-addiction specialists, including some in world-leading laboratories in Britain, think it's now time...

  • May 15- The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca, Johnson& Johnson and Eli Lilly in partnership with Boehringer Ingleheim may cause dangerously high levels of blood acids that could require hospitalization. The FDA said its Adverse Event Reporting System database...

  • U.S. FDA warns on newer class of type 2 diabetes drugs Friday, 15 May 2015 | 11:06 AM ET

    May 15- The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drug sold by AstraZeneca, Johnson& Johnson and Eli Lilly in partnership with Boehringer Ingleheim may a cause dangerously high levels of blood acids that could require hospitalization. They include AstraZeneca's Farxiga, J&J's Invokana and...

  • Jim O’Neill thinks we need $2B to fund new drugs Thursday, 14 May 2015 | 11:13 AM ET

    As the list of drug-resistant bacteria grows, more research into new antibiotics is needed, according to ex-Goldman Sachs economist Jim O’Neill, who was also made U.K. Commercial Secretary on Thursday.

  • May 13- Details from a late-stage trial of Puma Biotechnology's experimental breast cancer pill neratinib showed that it improved disease-free survival for certain breast cancer patients, but only by 2.3 months. Puma shares slid 25 percent after hours following release of the findings on Wednesday by the American Society of Clinical Oncology ahead of its...

  • A study conducted at the University of Sydney found that nicotinamide, a form of vitamin B3, reduced by 23 percent the incidence of new, non-melanoma skin cancers in people who had at least two of the cancers in the previous five years. "It's a cheap vitamin... one could be generous about starting it early if that's a preference," said Dr Peter Paul Yu, ASCO president and...

  • Investors were waiting for news that could move share prices from many bigger companies including Bristol-Meyers Squibb Co, Amgen Inc and Celgene Corp. Hot topics at the American Society of Clinical Oncology conference in Chicago will include immuno oncology and CAR-T cell therapies. Shares in Juno Therapeutics Inc, Kite Pharma Inc, BlueBird Bio Inc and...

  • May 12- A trial assessing the cardiovascular safety of obesity drug Contrave, made by Orexigen Therapeutics Inc and Takeda Pharmaceutical Co Ltd, was terminated on Tuesday due to unauthorized release of study data. A statement from Cleveland Clinic, which was conducting the trial, said the study was being halted as unauthorized release of trial data by...

  • *Tie-up with Montreal scientists on heart disease genes. LONDON, May 13- AstraZeneca is diving deeper into personalised healthcare with two projects that move the concept beyond cancer into respiratory disorders and heart disease. To redress the balance, AstraZeneca said on Wednesday it had signed two deals, one with Abbott Laboratories for a diagnostic test...